PI3K/Akt/mTOR inhibitors in breast cancer
Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition of the pathway, and phase I to Ⅲ trials involving inhibitors of the pathway have been or are being conducted in solid tumors...
Main Authors: | Joycelyn JX Lee, Kiley Loh, Yoon-Sim Yap |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2015-12-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/888 |
Similar Items
-
Targeting PI3K/Akt/mTOR Signaling In Cancer
by: Camillo ePorta, et al.
Published: (2014-04-01) -
Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products
by: Iksen, et al.
Published: (2021-07-01) -
Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade
by: Yan Chen Shang, et al.
Published: (2012-10-01) -
Suppression of AKT-mTOR signal pathway enhances osteogenic/dentinogenic capacity of stem cells from apical papilla
by: Yosuke Tanaka, et al.
Published: (2018-11-01) -
The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
by: Jessica Lawrence, et al.
Published: (2018-03-01)